UV1 plus pembrolizumab in recurrent and metastatic head and neck squamous cell carcinoma: safe, immunogenic, but lacking efficacy.
Saved in:
| Title: | UV1 plus pembrolizumab in recurrent and metastatic head and neck squamous cell carcinoma: safe, immunogenic, but lacking efficacy. |
|---|---|
| Authors: | Flores G; Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA., Buchakjian MR; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Heft Neal M; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Brenner JC; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. |
| Source: | Translational cancer research [Transl Cancer Res] 2026 Mar 31; Vol. 15 (3), pp. 140. Date of Electronic Publication: 2026 Mar 24. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101585958 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2219-6803 (Electronic) Linking ISSN: 2218676X NLM ISO Abbreviation: Transl Cancer Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2219-6803 |
|---|---|
| DOI: | 10.21037/tcr-2025-1-2689 |
